Olusola Joseph
Family · Charlotte, NCNPI 1922470723
Payments from drug & device makers
Across 111 payments — averaging $16.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$333
- Lilly USA, LLC$231
- Pfizer$180
- Boehringer Ingelheim$142
- AstraZeneca$123
- Gilead$120
- plus $710 from 18 others
What the payments were for
- Food & beverage$1,838100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 24 | $333 |
| Lilly USA, LLC | 12 | $231 |
| Pfizer | 11 | $180 |
| Boehringer Ingelheim | 8 | $142 |
| AstraZeneca | 8 | $123 |
| Gilead | 6 | $120 |
| Johnson & Johnson | 8 | $118 |
| Novo Nordisk | 6 | $93 |
| Shield Therapeutics Inc | 5 | $88 |
| Bayer | 5 | $76 |
| Exact Sciences | 3 | $65 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $50 |
| Sanofi-aventis U.S. LLC | 1 | $24 |
| Dexcom, Inc. | 1 | $23 |
| Hologic Sales And Service, LLC | 1 | $21 |
| Cranial Technologies, Inc | 1 | $20 |
| GSK | 1 | $19 |
| Abbott | 1 | $18 |
| Optinose US, Inc. | 1 | $17 |
| Corcept Therapeutics | 1 | $17 |
| Axsome Therapeutics, Inc. | 1 | $16 |
| Organon | 1 | $16 |
| Nestle Healthcare Nutrition Inc. | 1 | $15 |
| Merck | 1 | $14 |
How this compares
$1,838 in reported general payments places this provider in the 80th percentile of 4,522 family providers in North Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 34 | $40,554 |
| FarxigaDapagliflozin Propanediol | 43 | $39,353 |
| JanuviaSitagliptin Phosphate | 16 | $15,997 |
| JardianceEmpagliflozin | 15 | $12,755 |
| EliquisApixaban | 11 | $9,861 |
| Omeprazole | 53 | $958 |
| Atorvastatin Calcium | 116 | $897 |
| Gabapentin | 37 | $689 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 12 | $568 |
| Amlodipine Besylate | 97 | $560 |
| Methocarbamol | 14 | $433 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 14 | $431 |
| Metformin Hcl ErMetformin Hcl | 35 | $424 |
| Trazodone Hcl | 23 | $421 |
| Lisinopril | 64 | $403 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $93 | $40,55434 claims |
| AstraZenecaFarxiga | $123 | $39,35343 claims |
| MerckJanuvia | $14 | $15,99716 claims |
| Boehringer IngelheimJardiance | $142 | $12,75515 claims |
| PfizerEliquis | $180 | $9,86111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,522 family providers in North Carolina.
Other family in Charlotte
- Debra ScottCharlotte$129K
- Lasherri LeathersCharlotte$89K
- Catherine ShahCharlotte$72K
- Jason HardinCharlotte$37K
- Laura ListonCharlotte$33K
- Marie KristensenCharlotte$30K
- Hadley DebergCharlotte$16K
- Morgan HubeliCharlotte$15K
- Trisha WootenCharlotte$15K
- Samantha GriffinCharlotte$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.